Nephros (NASDAQ:NEPH - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.
Several other research analysts also recently issued reports on NEPH. Maxim Group lifted their price objective on Nephros from $4.50 to $6.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Nephros to a "strong-buy" rating in a research note on Saturday, October 18th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Nephros currently has an average rating of "Moderate Buy" and a consensus target price of $5.50.
Check Out Our Latest Stock Report on Nephros
Nephros Trading Up 1.8%
Shares of NEPH opened at $5.23 on Friday. Nephros has a twelve month low of $1.38 and a twelve month high of $5.98. The stock's 50 day moving average is $4.53 and its two-hundred day moving average is $3.58. The firm has a market capitalization of $55.44 million, a PE ratio of 43.58 and a beta of 1.32.
Nephros (NASDAQ:NEPH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.04. Nephros had a return on equity of 14.89% and a net margin of 7.95%.The company had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.60 million.
Institutional Investors Weigh In On Nephros
An institutional investor recently raised its position in Nephros stock. Topline Capital Management LLC increased its holdings in shares of Nephros Inc. (NASDAQ:NEPH - Free Report) by 13.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 477,449 shares of the company's stock after acquiring an additional 55,360 shares during the quarter. Topline Capital Management LLC owned approximately 4.50% of Nephros worth $1,953,000 at the end of the most recent quarter. 41.10% of the stock is currently owned by institutional investors.
Nephros Company Profile
(
Get Free Report)
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nephros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nephros wasn't on the list.
While Nephros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
